Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Currently, there is no proven association between the BRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kähler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard, Goldinger, Simone M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591284/
https://www.ncbi.nlm.nih.gov/pubmed/26426340
http://dx.doi.org/10.1371/journal.pone.0139438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591284/
https://www.ncbi.nlm.nih.gov/pubmed/26426340
http://dx.doi.org/10.1371/journal.pone.0139438

Ejemplares similares